Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 7.9% year on year to $206.7 million. The company expects the full year’s revenue to be around $855 million, close to analysts’ estimates. Its non-GAAP profit of $0.14 per share was 54.1% above analysts’ consensus estimates.
Is now the time to buy INSP? Find out in our full research report (it’s free for active Edge members).
Inspire Medical Systems (INSP) Q3 2026 highlights:
- Revenue $206.7 million vs S&P analysts’ estimates of $204.5 million (7.9% year-on-year decline, 1.1% beat)
- Adjusted EPS $0.14 vs S&P analysts’ estimates of $0.09 (54.1% beat)
- Adjusted EBITDA $37.86 million vs analyst estimates of $35.66 million (18.3% margin, 6.1% beat)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $855 million at the midpoint
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $1.30 at the midpoint, a 4% increase
- Operating margin -13.9%, down from 4.3% in the same quarter last year
- Market capitalization $1.94 billion
StockStory’s take
Inspire Medical Systems’ third quarter was shaped by ongoing adjustments to coding and reimbursement processes, which management highlighted as a central factor in the year-on-year revenue decline. CEO Tim Herbert emphasized the company’s efforts to support physicians and implanting centers in adapting to new billing procedures, noting, “centers have gained experience with a stable, temporary billing framework.” The sequential revenue increase was attributed to stronger-than-expected U.S. performance, even as international markets lagged due to inventory destocking. Management also pointed to increased gross margins from a higher sales mix of Inspire V devices and underscored the impact of restructuring and legal expenses on overall operating results.
Looking ahead, Inspire Medical Systems expects a more stable coding environment and targeted growth investments to drive a return to low single-digit revenue growth in 2027. Management is prioritizing initiatives that expand patient access, such as adding field roles in high-potential markets and enhancing digital engagement. CFO Matt Osberg explained, “We are directing funds to our highest impact revenue initiatives, which center on expanding access to care, improving patient education, and helping patients navigate their treatment journey.” The upcoming introduction of a dedicated Category I CPT code in 2028 is expected to further streamline reimbursement and support future growth.
Key insights from management’s remarks
Management attributed the quarter’s results to coding-related disruptions, international inventory adjustments, and investments in patient access and product development.
-
U.S. growth offsets international softness: Management cited stronger-than-expected U.S. results as a key driver, while international revenue was hindered by destocking activities, particularly in Germany.
-
Coding and reimbursement headwinds: Adjustments to coding and reimbursement processes continued to impact revenues, with management estimating a $30 million negative effect in the quarter. CEO Tim Herbert noted increasing comfort among centers using the new billing framework, which is expected to persist into 2027.
-
Inspire V adoption and clinical data: The company reported strong uptake of the Inspire V device, now representing the majority of procedures. Recent studies and conference presentations demonstrated improved patient outcomes and higher gross margins relative to previous device generations.
-
Project Horizon investments: The restructuring under Project Horizon freed up approximately $30 million annually for growth initiatives. These funds are being used to expand field roles, enhance marketing efforts, and invest in digital tools to improve patient pathways and engagement.
-
International market update: Core European markets like Germany and France remain focus areas, with management expecting recovery from recent declines and continued expansion, especially in France where national coverage is relatively new.
Drivers of future performance
Inspire Medical Systems’ outlook is supported by a stabilizing coding environment, targeted commercial investments, and anticipated reimbursement changes.
-
Coding clarity and reimbursement: Management believes the move toward a dedicated Category I CPT code in 2028 will simplify billing for all payers, reducing administrative burdens and potentially expanding patient access. The current temporary framework is expected to remain stable until then.
-
Patient flow and field expansion: The company is investing in additional field roles in approximately 40 high-potential U.S. markets to boost patient pipeline and center capacity. These efforts, alongside enhanced digital engagement and marketing initiatives, are expected to accelerate adoption and patient throughput.
-
Battery replacements and new channels: Inspire anticipates battery replacements will become a more meaningful revenue contributor, while early work targeting cardiology referral channels may unlock new patient segments. Management highlighted ongoing monitoring of market dynamics, including the impact of GLP-1 medications on patient eligibility and growth.
Catalysts in upcoming quarters
Over the coming quarters, our analysts will be watching (1) the pace at which coding and reimbursement clarity translates to improved patient volumes, (2) the effectiveness of Project Horizon-driven investments in expanding patient access and market share, and (3) the recovery trajectory in international markets, particularly Europe. Progress on next-generation product development and successful execution of digital engagement initiatives will also be important indicators of Inspire’s ability to accelerate growth in 2027 and beyond.
Inspire Medical Systems currently trades at $66.40, down from $67.21 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Stocks that trumped tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.